Abstract library

17 results for "Smith".
#459 Differential Claudin-1 Gene Expression in Neural Crest-Derived Tumors of Common Embryological Origin
Introduction: Pheochromocytoma and paraganglioma are neural crest-derived tumors originating from chromaffin cells, with the former being intra–adrenal in location, while the latter are extra-adrenal.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Miss Beatrice Philip
Authors: Philip B, Smith R, Lam A
Keywords: Claudin-1
#681 The Use of Capsule Endoscopy for Assessment of Neuroendocrine Tumors of Unknown Primary Tumor Location
Introduction: Recent studies suggest that capsule endoscopy (CE) should be implemented in diagnostic work-up in patients suspected to have small bowel (SB) tumors. SB accounts for the primary tumor site in 80%-85% of patients with intestinal neuroendocrine tumors (NET). In 10%-15% of patients diagnosed with metastasized NET, the primary tumor site remains obscure.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: PhD Panagiotis Drymousis
#857 Video Capsule Endoscopy as a Tool to Detect Small Bowel Neuroendocrine Tumors
Introduction: Recent studies suggest that video capsule endoscopy (CE) should be implemented in diagnostic work-up in patients with suspected small bowel tumors. Small bowel is the primary site in 80%-85% of patients with intestinal neuroendocrine tumors (NET). In 10%-15% of patients diagnosed with metastasized NET, the localization of the primary tumors remains obscure.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Helen Miller
#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)
Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Philippe Ruszniewski
Keywords: PRO
#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study
Introduction: CS associated with NETs can have a negative impact on patients’ QoL.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Philippe Ruszniewski
Keywords: quality of life
#1263 Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
Introduction: 68GaDOTA TATE imaging of patients with neuroendocrine tumours has shown that tumour sequestration is a major factor leading to a sink effect that decreases activity concentration in healthy tissues, particularly the renal parenchyma.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Steven Goodman
Keywords: dosimetry, PRRT
#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Keywords: sutent, OS
#1425 Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate.
Introduction: Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Catherine Lucas
Authors: Lucas C, Goodman S, Smith J, Burge M, ...
#1591 Patient-Reported Preferences in Treatments Approved in Neuroendocrine Tumors: A National Survey from the French Group of Endocrine Tumors
Introduction: Patients with advanced neuroendocrine tumors (NETs) benefit from an increasing number of treatments. The patient’s preference could help physicians to choose among these options
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr Arnaud Plante
Authors: Plante A, Baudin E, Do Cao C, Hentic O, ...
#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Côme Lepage
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.